RAF Suppression Synergizes with MEK Inhibition in KRAS Mutant Cancer Cells

KRAS is the most frequently mutated oncogene in human cancer, yet no therapies are available to treat KRAS mutant cancers. We used two independent reverse genetic approaches to identify components of the RAS-signaling pathways required for growth of KRAS mutant tumors. Small interfering RNA (siRNA)...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Cell reports (Cambridge) Ročník 8; číslo 5; s. 1475 - 1483
Hlavní autori:	Lamba, Simona, Russo, Mariangela, Sun, Chong, Lazzari, Luca, Cancelliere, Carlotta, Grernrum, Wipawadee, Lieftink, Cor, Bernards, Rene, Di Nicolantonio, Federica, Bardelli, Alberto
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Elsevier Inc 11.09.2014 Elsevier
Predmet:	Antineoplastic Agents - pharmacology Apoptosis Benzimidazoles - pharmacology Cell Line, Tumor Colorectal Neoplasms - genetics Colorectal Neoplasms - metabolism Humans MAP Kinase Signaling System Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors Mitogen-Activated Protein Kinase Kinases - genetics Mitogen-Activated Protein Kinase Kinases - metabolism Mutation Protein Kinase Inhibitors - pharmacology Protein Multimerization Proto-Oncogene Proteins - genetics Proto-Oncogene Proteins - metabolism Proto-Oncogene Proteins p21(ras) raf Kinases - antagonists & inhibitors raf Kinases - genetics raf Kinases - metabolism ras Proteins - genetics ras Proteins - metabolism
ISSN:	2211-1247, 2211-1247
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!